MMRV vaccine

Recommendations

The MMRV vaccine, a combined MMR and varicella vaccine, simplifies the administration of the vaccines.

Adverse events

Rare but serious adverse events reported following Proquad vaccination include allergic reactions, including swelling of the lips, tongue, or face; difficulty breathing or closing of the throat; hives; paleness; weakness; dizziness; a fast heartbeat; deafness; long-term seizures, coma, or lowered consciousness; seizures (jerking or staring) caused by fever; or temporary low platelet count.

For children aged two and younger, the MMRV vaccine is associated with significantly more adverse events compared to separate administration of MMR and varicella vaccinations on the same day. There are 4.3 additional febrile seizures per 10,000 vaccinated children (95% CI 2.6–5.6), 7.5 additional mostly mild fever episodes per 100 vaccinated children (95% CI, 5.4–9.4) and 1.1 additional measles-like rash per 100 children (95% CI, 0.2–1.8). Febrile seizures caused by the MMRV vaccine occur 7 to 10 days after vaccination. In children age 4–6, there is no evidence for an increased risk in febrile seizures after the administration of Proquad compared to the separate administration of MMR and Varicella vaccines.

Legal status

Proquad was approved for medical use in the United States in September 2005, in the European Union in April 2006, in Australia in February 2007, and in Canada in May 2014.

Priorix Tetra was approved for medical use in Australia in November 2005, and in Canada in June 2008.

References

References

1. (16 October 2019). "Measles virus vaccine/mumps virus vaccine/rubella virus vaccine/varicella virus vaccine (Proquad) Use During Pregnancy".
2. (9 May 2014). "Proquad Product information".
3. (4 June 2008). "Priorix Tetra Product information".
4. (5 November 2024). "Proquad- measles, mumps, rubella and varicella virus vaccine live injection, powder, lyophilized, for suspension".
5. (August 2018). "MMR and MMRV vaccines". Vaccine.
6. (December 2015). "Measles 50 Years After Use of Measles Vaccine". Infectious Disease Clinics of North America.
7. (November 2018). "Measles: information about the disease and vaccines Questions and Answers".
8. (2003). "Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella". Drugs.
9. "GlaxoSmithKline Clinical Trial Register".
10. (14 December 2012). "Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines".
11. (4 June 2018). "Priorix-tetra".
12. (November 2015). "Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra) Compared to Separate MMR + V Vaccination". Drug Safety.
13. (19 October 2019). "PEI Table of vaccines for measles with a valid marketing authorisation".
14. (July 2007). "Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine". The Pediatric Infectious Disease Journal.
15. (21 May 2010). "MMRV (Measles, Mumps, Rubella & Varicella) VIS". CDC.
16. (July 2010). "Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures". Pediatrics.
17. (August 2005). "CBER clinical review of studies submitted in support of licensure of Proquad". US Food and Drug Administration.
18. "Proquad".
19. "Proquad".
20. (6 April 2006). "Proquad EPAR".
21. (26 May 2022). "Proquad measles mumps rubella varicella live virus vaccine injection vial with prefilled diluent syringe (126157)".
22. (26 May 2022). "Priorix-Tetra vaccine 0.5mL powder for injection vial with diluent syringe (107286)".